Xenon shares plunge after lead drug trial setback
Xenon said it submitted late Thursday, but the lead drug trial outcome is described as a clinical setback and the stock is reported to be having its worst day since 2017.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.